FDA Panel Votes Against Accelerated Approval of AstraZeneca Ovarian Cancer Drug

June 26, 2014 7:11 AM

14 0

LONDON--AstraZeneca PLC (AZN.LN) said Thursday the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee voted against accelerated approval of investigational ovarian cancer drug olaparib.

AstraZeneca said the FDA advisory committee voted 11 to 2 that current evidence from clinical studies don't support accelerated approval of olaparib "as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have the germline BRCA mutation, and who are in complete or p...

Read more

To category page